

PEB TO CONTINUE PROVIDING ESSENTIAL DIAGNOSTIC SERVICES

Pacific Edge will continue to provide essential cancer diagnostic services during COVID-19 shutdown in both New Zealand and USA

Cancer diagnostic company, Pacific Edge, advises that its medical and diagnostic services laboratories in both New Zealand and the USA have been identified as Essential Businesses and that they are operating during the Government-directed COVID-19 shutdowns.

The Pacific Edge laboratories, in New Zealand and the USA, will continue to operate with a full staff of technical and supervisory team members providing Cxbladder analysis services to primary care and secondary care physicians.

The laboratories are controlled access, clean molecular-diagnostic environments and additional safety protocols have been put in place to enhance the operating environment safety for staff providing services in these challenging circumstances. These include two separate operations teams with only one team on site at a time, safe distancing, extra cleaning and sanitisation. Remote working has been enabled for all other employees.

The Company has sufficient laboratory consumables to meet expected demand, with support from its suppliers to ensure ongoing provision of necessary components.

To help reduce the spread of COVID-19, General Practitioners (GPs) in New Zealand have rapidly moved to doing most of their patient consultations by phone, email and video¹. Pacific Edge is uniquely positioned to support medical practitioners in this challenging time by providing timely evaluation and diagnosis of bladder cancer for their patients in self-isolation at home, with a minimum of face-to-face contact.

CEO of Pacific Edge, David Darling, said: "For many diseases and illnesses, a timely diagnosis can have a significant impact on health outcomes. In this challenging healthcare environment, remote consultations and the ability for patients to supply Cxbladder test samples from home will all help to take the pressure off the healthcare system, while continuing to provide patients with timely and appropriate care.

"This is a rapidly changing situation. We are closely monitoring our customer's needs, the market and the operating environment and we will continue to keep the market updated on any further developments."

ENDS

¹ https://www.rnzcgp.org.nz/RNZCGP/News/College_news/2020/GPs-open-for-business.aspx

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacifiedge.co.nz www.pacifiedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.